The following discussion of our operations and financial condition should be
read in conjunction with the condensed consolidated financial statements and
notes thereto included elsewhere in this Quarterly Report on Form 10-Q.



FORWARD-LOOKING STATEMENTS



This Quarterly Report on Form 10-Q contains forward-looking statements within
the meaning of the "safe harbor" provisions under section 21E of the Securities
and Exchange Act of 1934 and the Private Securities Litigation Act of 1995. We
use forward-looking statements in our description of our plans and objectives
for future operations and assumptions underlying these plans and objectives.
Forward-looking terminology includes the words "may", "expects", "believes",
"anticipates", "intends", "forecasts", "projects", or similar terms, variations
of such terms or the negative of such terms. These forward-looking statements
are based on management's current expectations and are subject to factors and
uncertainties which could cause actual results to differ materially from those
described in such forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained in this Form 10-Q to reflect any change in
our expectations or any changes in events, conditions or circumstances on which
any forward-looking statement is based. Factors which could cause such results
to differ materially from those described in the forward-looking statements
include those set forth under "Item. 1 Description of Business - Risk Factors"
and elsewhere in or incorporated by reference into our Annual Report on Form
10-K for the year ended March 31, 2022.



BUSINESS OVERVIEW



The Company is a technology-based developer and manufacturer of diversified
lines of products and derives revenue from the production and sale of
electronics for medical devices and other applications; environmentally safe
chemical products for industrial, medical and cosmetic uses; and, research,
development, regulatory and engineering services. The Company has increased
internal research and development by utilizing their engineering resources to
advance their own proprietary medical device technologies.



The Company is a corporation that was organized under the laws of the State of
Delaware on November 24, 1969. Our operations are conducted through ADM and its
subsidiary Sonotron.


RESULTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2022 AS COMPARED TO SEPTEMBER 30, 2021.





For the three months ended September 30,
2022
                                           Chemical       Electronics       Engineering         Total
Revenue                                    $ 345,395     $     633,857     $     161,016     $ 1,140,268
Cost of Sales                                210,139           336,875            35,221         582,235
Gross Profit                                 135,256           296,982           125,795         558,033
Gross Profit Percentage                           39 %              47 %              78 %            49 %

Operating Expenses                           134,238           253,756            67,147         455,141
Operating Income (Loss)                        1,018            43,226            58,648         102,892
Other income (expenses)                         (754 )          (1,631 )    

(464 ) (2,849 )



Income (loss) before benefit from income
taxes                                      $     264     $      41,595     $      58,184     $   100,043




                                       14

--------------------------------------------------------------------------------





For the three months ended
September 30, 2021
                                  Chemical       Electronics       Engineering        Total
Revenue                          $  370,826     $     341,084     $     139,949     $  851,859
Cost of Sales                       203,890           246,655            38,650        489,195
Gross Profit                        166,936            94,429           101,299        362,664
Gross Profit Percentage                  45 %              28 %              72 %           43 %

Operating Expenses                  397,792           344,571           172,875        915,238
Operating Income (Loss)            (230,856 )        (250,142 )         (71,576 )     (552,574 )
Other income (expenses)             154,425           129,217            75,458        359,100

Income (loss) before benefit
from income taxes                $  (76,431 )   $    (120,925 )   $       3,882     $ (193,474 )


Variance
                                  Chemical       Electronics       Engineering        Total
Revenue                          $  (25,431 )   $     292,773     $      21,067     $  288,409
Cost of Sales                         6,249            90,220            (3,429 )       93,040
Gross Profit                        (31,680 )         202,553            24,496        195,369
Gross Profit Percentage                  -6 %              19 %               6 %            6 %

Operating Expenses                 (263,554 )         (90,815 )        (105,728 )     (460,097 )
Operating Income (Loss)             231,874           293,368           130,224        655,466
Other income (expenses)            (155,179 )        (130,848 )         (75,922 )     (361,949 )

Income (loss) before benefit
from income taxes                $   76,695     $     162,520     $      54,302     $  293,517

For the six months ended September 30, 2022


                                              Chemical      Electronics       Engineering         Total
Revenue                                       $ 717,570     $  1,098,549     $     245,557     $ 2,061,676
Cost of Sales                                   399,671          659,380            61,533       1,120,584
Gross Profit                                    317,899          439,169           184,024         941,092
Gross Profit Percentage                              44 %             40 %              75 %            46 %

Operating Expenses                              305,488          462,598           104,739         872,825
Operating Income (Loss)                          12,411          (23,429 )          79,285          68,267
Other income (expenses)                          (2,411 )         (3,652 )            (827 )        (6,890 )
Income before provision for income taxes      $  10,000     $    (27,081 )   $      78,458     $    61,377




                                       15

--------------------------------------------------------------------------------




For the six months ended September 30,
2021
                                            Chemical       Electronics       Engineering         Total
Revenue                                    $  686,083     $     563,658     $     323,476     $ 1,573,217
Cost of Sales                                 378,463           455,758            74,350         908,571
Gross Profit                                  307,620           107,900           249,126         664,646
Gross Profit Percentage                            45 %              19 %              77 %            42 %

Operating Expenses                            549,583           451,515           259,119       1,260,217
Operating Income (Loss)                      (241,963 )        (343,615 )          (9,993 )      (595,571 )
Other income (expenses)                       153,908           128,853     

75,164 357,925



Income before provision for income taxes   $  (88,055 )   $    (214,762 )   $      65,171     $  (237,646 )

Variance
                                            Chemical       Electronics       Engineering         Total
Revenue                                    $   31,487     $     534,891     $     (77,919 )   $   488,459
Cost of Sales                                  21,208           203,622           (12,817 )       212,013
Gross Profit                                   10,279           331,269           (65,102 )       276,446
Gross Profit Percentage                            -1 %              21 %              -2 %             3 %

Operating Expenses                           (244,095 )          11,083          (154,380 )      (387,392 )
Operating Income (Loss)                       254,374           320,186            89,278         663,838
Other income (expenses)                      (156,319 )        (132,505 )   

(75,991 ) (364,815 )



Income (loss) before benefit from income
taxes                                      $   98,055     $     187,681     $      13,287     $   299,023




Revenues for the three months ended September 30, 2022 increased by $288,409.
The increase is a result of increased sales of $21,067 in the Engineering
segment and $292,773 in the Electronics segment offset by a decrease of $25,431
in the Chemical segment.


Gross profit for the three months ended September 30, 2022 increased by $195,369. The increase in gross profit resulted primarily from increased sales in Electronics and Engineering sales.





Revenues for the six months ended September 30, 2022 increased by $488,459. The
increase is a result of increased sales of $31,487 in the Chemical segment and
$534,891 in the Electronics segment offset by a decrease of $77,919 in the
Engineering segment.



Gross profit for the six months ended September 30, 2022 increased by $276,446. The increase in gross profit resulted primarily from increased sales in Electronics and Chemical sales.





We are highly dependent upon certain customers. During the three months
ended September 30, 2022, three customers accounted for 65% of our net revenue.
Net revenues from foreign customers for the three months ended September 30,
2022 was $86,296 or 8%.



During the three months ended September 30, 2021, two customers accounted for
51% of our net revenue. Net revenues from foreign customers for the three months
ended September 30, 2021 was $75,541 or 9%.



During the six months ended September 30, 2022, two customers accounted for 50% of our net revenue. Net revenues from foreign customers for the six months ended September 30, 2022 was $211,571 or 10%.





The complete loss of or significant reduction in business from, or a material
adverse change in the financial condition of any of our customers could cause a
material and adverse change in our revenues and operating results.



Income from operations for the three months ended September 30, 2022 was $102,892 compared to loss from operations for the three months ended September 30, 2021 of ($552,574).

Other income decreased $361,949 for the three months ended September 30, 2022. The decrease is attributable to the PPP forgiveness of $361,275 in 2021.

Other income decreased $364,815 for the six months ended September 30, 2022. The decrease is attributable to the PPP forgiveness of $361,275 in 2021.





The foregoing resulted in net income before provision for income taxes for the
three and six months ended September 30, 2022 of $61,377 and $100,043,
respectively. Earnings per share were $0.00 for the three and six months ended
September 30, 2022.



                                       16

--------------------------------------------------------------------------------

LIQUIDITY AND CAPITAL RESOURCES





At September 30, 2022, we had cash and cash equivalents of $854,493 as compared
to $1,038,498 at March 31, 2022. The $184,005 decrease was primarily the result
of cash used in operations during the six-month period in the amount of $63,889
and cash used in financing activities of $120,116. Our cash will continue to be
used for increased marketing costs, and increased production labor costs all in
an attempt to increase our revenue, as well as increased expenditures for our
internal R&D. We expect to have enough cash to fund operations for the next
twelve months.



Below is a summary of our cash flow for the three-month ending periods indicated:

© Edgar Online, source Glimpses